{"id":994398,"date":"2026-08-12T17:31:55","date_gmt":"2026-08-12T21:31:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-announces-financial-results-for-the-second-quarter-2026-and-provides-a-corporate-update\/"},"modified":"2026-08-12T17:31:55","modified_gmt":"2026-08-12T21:31:55","slug":"armata-pharmaceuticals-announces-financial-results-for-the-second-quarter-2026-and-provides-a-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-announces-financial-results-for-the-second-quarter-2026-and-provides-a-corporate-update\/","title":{"rendered":"Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LOS ANGELES<\/span>, Aug. 12, 2026<\/span> \/PRNewswire\/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update.<\/p>\n

\n

\n \"Armata\n <\/p>\n<\/p><\/div>\n

“We continue to finalize activities required to initiate a pivotal Phase 3 superiority study of AP-SA02 in complicated S. aureus <\/i>bacteremia in the second half of 2026,” said Dr. Deborah Birx, Chief Executive Officer of Armata. “We recently submitted the Phase 3 protocol to the FDA, responded to the Agency’s End-of-Phase 2 meeting minutes, and continued to advance manufacturing, each of these key milestones supporting study initiation. Complicated S. aureus <\/i>bacteremia is associated with substantial morbidity and mortality, underscoring the need for new treatments. We believe AP-SA02, a novel intravenous phage therapeutic, has the potential to be a valuable and differentiated approach for patients in need.”<\/p>\n

“We also achieved several additional important milestones for AP-SA02, including FDA agreement on our Agreed Initial Pediatric Study Plan, granting of Fast Track designation by the FDA, and receipt of additional non-dilutive funding from our partners at the U.S. Department of War. We were pleased to promote David House to Chief Financial Officer, ensuring we have the financial leadership in place to execute our late-stage clinical development goals,” concluded Dr. Birx.<\/p>\n

\n Second Quarter 2026 and Recent Developments:<\/b>\n <\/p>\n

\n
\n Clinical, Regulatory, Manufacturing, and Operational Progress<\/i>
\n <\/b>\n <\/p>\n

Armata has made significant progress across clinical, regulatory, manufacturing, and operational fronts supporting advancement of AP-SA02, the Company’s intravenously administered Staphylococcus aureus<\/i>\u00a0(“S. aureus<\/i>“) multi-phage product candidate, toward a Phase 3 superiority study for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus<\/i>\u00a0(“MSSA”) or methicillin-resistant S. aureus<\/i>\u00a0(“MRSA”). Collectively, these milestones support the planned pivotal Phase 3 superiority study, expected to initiate in the second half of 2026, and designed to support a future Biologics License Application (“BLA”) for AP-SA02.<\/p>\n

\n Clinical<\/u>\n <\/p>\n